Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Pharmacogenetic association between alox5 promoter genotype and the response to anti-asthma treatment

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Drazen, J. M.
  • Yandava, C. N.
  • Dube, L.
  • Szczerback, N.
  • Hippensteel, R.
  • Pillari, A.
  • Israel, E.
  • Schork, Nicholas
  • Silverman, E. S.
  • Katz, D. A.
  • Drajesk, J.

publication date

  • June 1999

journal

  • Nature Genetics  Journal

abstract

  • Clinically similar asthma patients may develop airway obstruction by different mechanisms. Asthma treatments that specifically interfere with the 5-lipoxygenase (ALOX5) pathway provide a method to identify those patients in whom the products of the ALOX5 pathway (that is, the leukotrienes) contribute to the expression of the asthma phenotype. Failure of an asthma patient to respond to treatment with ALOX5-pathway modifiers indicates that leukotrienes are not critical to the expression of the asthmatic phenotype in that patient. We previously defined a family of DNA sequence variants in the core promoter of the gene ALOX5 (on chromosome 10q11.2) associated with diminished promoter-reporter activity in tissue culture. Because expression of ALOX5 is in part transcriptionally regulated, we reasoned that patients with these sequence variants may have diminished gene transcription, and therefore decreased ALOX5 product production and a diminished clinical response to treatment with a drug targeting this pathway. Such an effect indicates an interaction between gene promoter sequence variants and drug-treatment responses, that is, a pharmacogenetic effect of a promoter sequence on treatment responses.

subject areas

  • Alleles
  • Anti-Asthmatic Agents
  • Arachidonate 5-Lipoxygenase
  • Asthma
  • Gene Frequency
  • Genetic Variation
  • Humans
  • Hydroxyurea
  • Lipoxygenase Inhibitors
  • Phenotype
  • Promoter Regions, Genetic
  • Treatment Outcome
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 1061-4036

Digital Object Identifier (DOI)

  • 10.1038/9680

PubMed ID

  • 10369259
scroll to property group menus

Additional Document Info

start page

  • 168

end page

  • 170

volume

  • 22

issue

  • 2

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support